Working Together Towards a Common Vision
Basin Genomics is a growing team of scientists, patient advocates, and entrepreneurs committed to advancing the fight against oral cancer. Founded in 2018, our goal it is to increase accessibility and efficacy of oral cancer testing to improve health outcomes on a global scale.
Meet The Team
Jenna Baker, PhD
Founder & CEO
A broadly trained scientist with research across multiple disciplines, Jenna brings more than 20 years of life science experience in the academic, private, and government (NIH) sectors to Basin Genomics. By combining her background in computational and functional genomics with her leadership experience, she is helping Basin Genomics translate clinically relevant genomic signatures into advances in personalized clinical care
Anne Shiflett, MBA
Co-Founder & Chief Business Officer
As the Chief Business Officer for Basin Genomics, Anne brings over 30 years of managerial, financial, and accounting experience to Basin Genomics, most recently as Vice President, Finance and Administration at Catalent Pharma (Paragon Bioservices) where she was instrumental in the sale of Paragon to Catalent in May 2019. She has expertise in leading the start-up and rapid growth of new and emerging companies.
Joe brings over 25 years of global healthcare experience in oncology, infectious disease, and respiratory therapeutic areas. He led the introduction for Merck of the first HPV vaccine, Gardasil, and was responsible for the formation of numerous global research, commercial, & manufacturing partnerships. He is recognized for his many successes commercializing technologies and building new product markets.
Head of Marketing
Piper has over 20 global healthcare experience in IVD and Immunohematology, holding various sales and marketing positions. As Head of Marketing, he has led the global commercialization of six analytical analyzers and 25 assays, focusing on infectious disease, oncology, and cardiac markers. He has many successes in building differentiated value propositions and developing integrated sales and marketing campaigns. Additionally, he has experience forming global commercial & manufacturing partnerships that have greatly expanded customer value and broaden capabilities.
Jason is a survivor of stage 4 HPV oral cancer. Having won this battle in 2015, he is on a mission to stop anyone else from having to go through the same experiences he endured. He is the founder of Superman HPV, dedicated to providing information on HPV-related cancers and resources for support. Jason is also a successful businessman and is currently the Co-Founder & President of the Ashar Group.
Senior Strategy Advisor
David is a seasoned healthcare CEO and Combat Veteran with over 20 years of experience commercializing diagnostics. He has built and scaled multiple healthcare companies that resulted in successful exits to strategic buyers. He was the CEO at Armune BioScience, which sold to Exact Sciences [EXAS] in Dec. 2017, as well as the US President at Phadia US/AB, which sold to Thermo Fisher Scientific [TMO] Sept. 2011).
Lynn has been the President and CEO of the American Sexual Health Association and the National Cervical Cancer Coalition since 2006, advocating for HPV vaccination and testing. She works closely with colleague organizations, from the American Sexual Transmitted Diseases Association, the National Coalition of STD Directors, and the Centers for Disease Control and Prevention.
Anna Giuliano, PhD
Dr. Giuliano is the Founding Director of the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center. Her work has contributed significantly to our understanding of the rate at which HPV infections are acquired and cleared, the proportion that progress to disease, and also to HPV vaccine protection against multiple diseases in women and men.
Anna-Barbara Moscicki, MD
Anna-Barbara is a clinician and researcher at UCLA, with a specific focus on HPV. She is the Past President of American Society for Colposcopy and Cervical Pathology and serves on committees for the WHO, NIH, and ACS. She was the PI of one of the longest running HPV studies (+25 years). Her work was highly influential in forming the new cervical cancer screening guidelines in the US.